Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.52 |
| ▸ | CMA1 | P23946 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 4/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9834315 | 0.82 | GSK3B (0.45) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL31218442 | 0.79 | TDP2 (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL21979984 | 0.79 | TDP2 (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL20588667 | 0.78 | CMA1 (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL29502199 | 0.78 | CMA1 (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL31414332 | 0.77 | AHR (0.49) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL8545481 | 0.77 | AHR (0.49) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL5756908 | 0.74 | AHR (0.35) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL152272 | 0.73 | GSK3B (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL21552373 | 0.73 | PGR (0.45) | AHRCMA1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | AHR 2051/4885CMA1 4582/4885GSK3B 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.